SCHEMBL2406209

SCHEMBL2406209

CC(C)c1cc(C(=O)Nc2ccc(CC(=O)O)cc2)oc1C(C)C

nearest known ligand 0.59

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.59
CYP26A1 O43174 3/20 0.59
CYP26B1 Q9NR63 2/20 0.59
HSD17B10 Q99714 1/20 0.56
MITF O75030 1/20 0.55
NR1H4 Q96RI1 6/20 0.49
FFAR1 O14842 2/20 0.49
KDM4E B2RXH2 2/20 0.49
MEN1 O00255 1/20 0.49
TP53 P04637 1/20 0.49
GLA P06280 1/20 0.49
KMT2A Q03164 1/20 0.49
GAA P10253 1/20 0.49
ALDH1A1 P00352 2/20 0.48
POLB P06746 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2435054 0.89 NR1H4 (0.49) SMN1; SMN2CYP26A1CYP26B1HSD17B10MITF
SCHEMBL2406810 0.86 SMN1; SMN2 (0.52) SMN1; SMN2CYP26A1CYP26B1HSD17B10MEN1
SCHEMBL2406820 0.85 NPC1 (0.53) SMN1; SMN2CYP26A1CYP26B1HSD17B10MITF
SCHEMBL2405602 0.84 MAPT (0.52) SMN1; SMN2CYP26A1CYP26B1KDM4EMEN1
SCHEMBL2405592 0.82 SMN1; SMN2 (0.44) SMN1; SMN2CYP26A1CYP26B1KDM4ETP53
SCHEMBL2407431 0.81 THRB (0.55) SMN1; SMN2HSD17B10MEN1TP53KMT2A
SCHEMBL2405272 0.80 KMT2A (0.43) SMN1; SMN2CYP26A1CYP26B1KDM4EMEN1
SCHEMBL2411251 0.79 RARA (0.46) SMN1; SMN2CYP26A1CYP26B1HSD17B10MITF
SCHEMBL2405520 0.79 PKM (0.51) SMN1; SMN2CYP26A1CYP26B1HSD17B10KDM4E
SCHEMBL2410253 0.78 MEN1 (0.47) SMN1; SMN2CYP26A1CYP26B1KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722730-B2 5-membered heterocyclic compound RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2014-05-13 US disclosed
US-8722730-B2 5-membered heterocyclic compound RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2014-05-13 US disclosed
US-20110213156-A1 5-MEMBERED HETEROCYCLIC COMPOUND RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2011-09-01 US disclosed
US-20110213156-A1 5-MEMBERED HETEROCYCLIC COMPOUND RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2011-09-01 US disclosed
EP-2189445-A1 FIVE-MEMBERED HETEROCYCLIC COMPOUND Research Foundation Itsuu Laboratory (JP) 2010-05-26 EP disclosed
EP-2189445-A1 FIVE-MEMBERED HETEROCYCLIC COMPOUND Research Foundation Itsuu Laboratory (JP) 2010-05-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110213156-A1 5-MEMBERED HETEROCYCLIC COMPOUND RXRA, RXRG, RXRB SMN1; SMN2 2833/4885CYP26A1 231/4885CYP26B1 174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.